R&D
Market Access/ News/ News/ News/ R&D
US panel backs Omicron-targeting vaccines for booster campaigns
Phil Taylor
BioNTech, coronavirus, COVID-19, COVID-19 vaccine, fda, GlaxoSmithKline, Moderna, Novavax, Omicron, Pfizer, regulatory, variant
0 Comment
Market Access/ News/ News/ News/ R&D
Basilea preps key US filing for MRSA antibiotic ceftobiprole
Phil Taylor
antibiotic, Basilea, ceftobiprole, infectious diseases, MRSA, Zevtera
0 Comment
Study exposes lack of diversity in US cancer trials
Phil Taylor
Clario, clinical trials, diversity, Phesi
0 Comment
GSK hepatitis B hope bepirovirsen heads for phase 3 test
Phil Taylor
antisense drugs, bepirovirsen, GlaxoSmithKline, hepatitis B, infectious disease, Ionis Pharmaceuticals
0 Comment
Another Astellas gene therapy hits a safety hurdle
Phil Taylor
Astellas, gene therapy, Pompe disease, safety
0 Comment
Data backs AZ’s Wilson disease drug, but with a question mark
Phil Taylor
Alexion, AstraZeneca, rare disease, Wilson disease
0 Comment
Sarepta shares yo-yo as FDA places hold on Duchenne trial
Phil Taylor
Duchenne muscular dystrophy, Exondys 51, fda, rare disease, regulatory, safety, Sarepta, vesleteplirsen
0 Comment